Pharmaceutical News and Articles

Almost a Third of U.S. Retail Pharmacies Have Closed Since 2010

Illinois, Maine, Mississippi, New York, Pennsylvania, Rhode Island and Vermont. There, more than half of counties experienced a net decline in pharmacies.Black,

E. Coli Outbreak Linked to McDonald's Quarter Pounders Declared Over

a condition that can trigger kidney failure, according to the CDC.More informationThe CDC has more on E. coli.SOURCES U.S. Food and Drug Administration, health

Zepbound Bests Wegovy for Weight Loss in New Trial

Zepbound, the new GLP-1 weight-loss drug from Eli Lilly Co., has outperformed its main competitor, Wegovy, in a clinical trial funded by Lilly. Given the increa

Soleno Therapeutics Announces FDA Extension of Review Period for DCCR (Diazoxide Choline) Extended-Release Tablets in Prader-Willi Syndrome

Satsuma Pharmaceuticals and SNBL Receive FDA Acceptance of NDA Resubmission of STS101 for the Acute Treatment of Migraine With or Without Aura

Aquestive Therapeutics Announces Positive FDA Feedback and Reaffirms NDA Submission Guidance for Anaphylm (epinephrine) Sublingual Film

Aquestive Therapeutics, Inc. (NASDAQ AQST), a pharmaceutical company advancing medicines to bring meaningful improvement to patients lives through innovative sc

Syros Announces Topline Data from SELECT-MDS-1 Phase 3 Trial of Tamibarotene in Higher-Risk Myelodysplastic Syndrome with RARA Gene Overexpression

Syros Pharmaceuticals (NASDAQ SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic maligna

FDA Approves Yesintek (ustekinumab-kfce), a Biosimilar to Stelara

Lantern Pharma's Investigational Drug-Candidate, LP-184, Receives Second Fast Track Designation from FDA for Treatment of Triple Negative Breast Cancer (TNBC)

Lantern Pharma Inc. (NASDAQ LTRN), an artificial intelligence (AI) company dedicated to developing cancer therapies and transforming the cost, pace, and timelin

FDA Grants Breakthrough Therapy Designation to Sacituzumab Tirumotecan (sac-TMT) for the Treatment of Certain Patients With Previously Treated Advanced or Metastatic Nonsquamous Non-Small Cell Lung Cancer With EGFR Mutations

Merck (NYSE MRK), known as MSD outside of the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthroug